MX2021015110A - Prevencion de infecciones por virus altamente patogenico mediante aplicacion topica de povidona-yodada en membranas mucosas. - Google Patents

Prevencion de infecciones por virus altamente patogenico mediante aplicacion topica de povidona-yodada en membranas mucosas.

Info

Publication number
MX2021015110A
MX2021015110A MX2021015110A MX2021015110A MX2021015110A MX 2021015110 A MX2021015110 A MX 2021015110A MX 2021015110 A MX2021015110 A MX 2021015110A MX 2021015110 A MX2021015110 A MX 2021015110A MX 2021015110 A MX2021015110 A MX 2021015110A
Authority
MX
Mexico
Prior art keywords
virus
fever
pneumoniae
cause
iodine
Prior art date
Application number
MX2021015110A
Other languages
English (en)
Inventor
Peter Molloy
Stephen Goodall
Original Assignee
Firebrick Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902006A external-priority patent/AU2019902006A0/en
Application filed by Firebrick Pharma Ltd filed Critical Firebrick Pharma Ltd
Publication of MX2021015110A publication Critical patent/MX2021015110A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta invención está dirigida a métodos para la prevención de infecciones por virus altamente patógenos (HP) aplicando a las membranas mucosas nasales una preparación tópica que comprende el agente antimicrobiano de amplio espectro povidona yodada (PVP-I). Dichos virus incluyen el SARS y los coronavirus MERS, como el SARS-CoV-2 (que causa el COVID-19), los filoviridae como el virus del Ébola (EBOV), el virus de Marburg (MARV), el virus de Sudán (SUDV), el virus del bosque de Tai (TAFV). y virus Bundibugyo (BDBV), virus de influenza pandémica como H5N1, H5N9, H7N3, H7N7, H9N2 y H1N1, y Arenaviridae que causan fiebre de Lassa, Junin y Machupo, Bunyaviridae que causan fiebre hemorrágica de Crimea-Congo, fiebre hemorrágica de Crimea-Congo, fiebre del Valle del Rift, hemorragia de Hanta fiebres y Flaviviridae que causan fiebre amarilla, dengue, fiebre hemorrágica de Omsk, enfermedad del bosque de Kyasanur. La presente invención se refiere además a un método para disminuir las infecciones secundarias de una infección viral primaria por HP, causada por bacterias u hongos tales como Mycoplasma pneumoniae, S. aureus, K. pneumoniae, S. pneumoniae, M. catarrhalis, P. aeruginosa, S pyogenes o Streptococcus agalactiae.
MX2021015110A 2019-06-10 2020-06-10 Prevencion de infecciones por virus altamente patogenico mediante aplicacion topica de povidona-yodada en membranas mucosas. MX2021015110A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902006A AU2019902006A0 (en) 2019-06-10 Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2020900489A AU2020900489A0 (en) 2020-02-20 Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
PCT/AU2020/050586 WO2020232515A1 (en) 2019-06-10 2020-06-10 Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes

Publications (1)

Publication Number Publication Date
MX2021015110A true MX2021015110A (es) 2022-02-22

Family

ID=73459166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015110A MX2021015110A (es) 2019-06-10 2020-06-10 Prevencion de infecciones por virus altamente patogenico mediante aplicacion topica de povidona-yodada en membranas mucosas.

Country Status (14)

Country Link
US (3) US11246887B2 (es)
EP (1) EP3980031A4 (es)
JP (1) JP2022538711A (es)
KR (1) KR20220018570A (es)
CN (1) CN114258303A (es)
AU (1) AU2020280226A1 (es)
BR (1) BR112021024916A2 (es)
CA (1) CA3141483A1 (es)
CL (1) CL2021003208A1 (es)
IL (1) IL288742A (es)
MX (1) MX2021015110A (es)
SG (1) SG11202112735QA (es)
WO (1) WO2020232515A1 (es)
ZA (1) ZA202109360B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3141483A1 (en) 2019-06-10 2020-11-26 Firebrick Pharma Limited Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
US11179575B2 (en) 2019-10-15 2021-11-23 Cedars-Sinai Medical Center Internal ultraviolet therapy
NL2025641B1 (en) * 2020-04-17 2023-06-22 Veloce Biopharma Llc Methods and compositions for improved treatment of sinus disease
CA3180198A1 (en) * 2020-06-10 2021-12-16 Peter Molloy Improved virucidal formulations
CA3204015A1 (en) * 2020-12-31 2022-07-07 Ntby Moss Llc Formulations of a prophylactic nasal spray and methods of use and manufacture thereof
WO2022162254A1 (es) * 2021-02-01 2022-08-04 Dermopartners,S.L. Composición para su uso en forma de gotas nasales y nebulizadores como antiviral
IL308209A (en) * 2021-05-05 2024-01-01 Cedars Sinai Medical Center Exposure to UVA light increases mitochondrial antiviral protein expression in tracheal cells through cell-to-cell communication and its uses
FR3122572A1 (fr) * 2021-05-07 2022-11-11 Nadine GRISLAIN Composition pharmaceutique bioadhésive comprenant du PVPI
AU2021203846B2 (en) * 2021-06-10 2022-11-24 Firebrick Pharma Limited Virucidal formulations containing povidone-iodine
CO2021016391A1 (es) * 2021-11-30 2023-06-09 Quifarmedical Company S A S Composición farmacéutica líquida antiviral contra sars-cov-2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4523589A (en) 1983-06-29 1985-06-18 Krauser Robert S Method and apparatus for treating ailments
JPH04173726A (ja) 1990-11-05 1992-06-22 Nippon Zetotsuku Kk 歯磨剤組成物
US5126127A (en) 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions
JPH09151127A (ja) 1995-09-29 1997-06-10 Taisho Pharmaceut Co Ltd 咽頭疾患用組成物
JP2000169378A (ja) 1998-12-10 2000-06-20 Taisho Pharmaceut Co Ltd 咽頭疾患用組成物
US20060122082A1 (en) 2000-02-17 2006-06-08 Leonard Paul Foam/spray producing compositions and dispensing system therefor
US6696041B2 (en) * 2002-03-20 2004-02-24 Richard L. Hansen Treatment of colds, flu like infections and other general nasal based infections with a solution containing iodine and other broad spectrum microbicides and a method for its use
AU2003263162B2 (en) * 2002-10-24 2009-05-07 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
JP2004352642A (ja) * 2003-05-29 2004-12-16 Meiji Seika Kaisha Ltd ウイルス感染症予防剤
CN1203864C (zh) 2003-07-23 2005-06-01 南京大学 聚维酮碘喷雾剂
US20080138438A1 (en) 2004-12-09 2008-06-12 The Dial Cprporation Compositions Having A High Antiviral And Antibacterial Efficacy
WO2012177251A1 (en) 2011-06-22 2012-12-27 Adeda Therapeutics Company Limited Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
CN103751274B (zh) * 2014-02-20 2016-08-17 河北旺达饲料兽药开发有限公司 一种治疗鸭、鹅黄病毒感染的药物组合物及其制备方法
JP2017522330A (ja) * 2014-07-23 2017-08-10 ファイアブリック・ファーマ・ピー・ティー・ワイ．エル・ティー・ディーＦｉｒｅｂｒｉｃｋ Ｐｈａｒｍａ Ｐｔｙ Ｌｔｄ ポビドンヨードを使用した感冒の治療および予防
KR20170033925A (ko) * 2015-09-17 2017-03-28 송경진 항바이러스 및 세균용 스프레이 조성물
KR101935250B1 (ko) * 2017-07-04 2019-01-04 김대황 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물
CA3141483A1 (en) * 2019-06-10 2020-11-26 Firebrick Pharma Limited Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes

Also Published As

Publication number Publication date
CL2021003208A1 (es) 2022-09-30
EP3980031A4 (en) 2022-08-17
SG11202112735QA (en) 2021-12-30
EP3980031A1 (en) 2022-04-13
KR20220018570A (ko) 2022-02-15
JP2022538711A (ja) 2022-09-06
US11969441B2 (en) 2024-04-30
CA3141483A1 (en) 2020-11-26
CN114258303A (zh) 2022-03-29
US20220088067A1 (en) 2022-03-24
BR112021024916A2 (pt) 2022-02-15
AU2020280226A1 (en) 2022-01-06
ZA202109360B (en) 2023-10-25
US20220168338A1 (en) 2022-06-02
US11246887B2 (en) 2022-02-15
US20200384016A1 (en) 2020-12-10
IL288742A (en) 2022-02-01
WO2020232515A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
ZA202109360B (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
CL2016000539A1 (es) Compuestos aza-piridina y usos de los mismos
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
MD20170046A2 (ro) Metode pentru tratamentul infecţiilor virale cu Filoviridae
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
EP3996716A4 (en) COMPOUNDS FOR TREATMENT OF INFLUENCE VIRUS INFECTION
EA201891278A1 (ru) Гетероциклические индолы для применения при инфекции, вызванной вирусом гриппа
PH12020551709A1 (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
BR112018069814A2 (pt) composição ou mistura, processo para preparação de uma mistura ou de uma composição, composição farmacêutica, e, método para tratamento terapêutico.
BR112014021612A2 (pt) composições e métodos para modulação da expressão de atxn3
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
EP3903823A3 (en) Antimicrobial peptides and methods of use thereof
WO2017078577A3 (ru) Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
BR112018072883A2 (pt) sistema de liberação de fármaco para a liberação de agentes antivirais
BR112017001803A2 (pt) aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos
CY1122496T1 (el) Παραγωγα αιμινης με αντιβακτηριακη και αντιιικη δραστικοτητα
WO2019125330A3 (en) Nasal decongestant compositions comprising dexpanthenol and sodium hyaluronate
WO2009152519A3 (en) Novel antiviral peptides against influenza virus
JP2020530499A5 (es)
JP2018150270A5 (es)
BR112022022263A2 (pt) Tratamento de infecções virais
EP3978026A4 (en) USE OF ANTHOCYANINE-ANIONIC POLYSACCHARIDE COMPLEXES IN THE PREVENTION OR TREATMENT OF INFLUENCE VIRUS A INFECTIONS
WO2007089562A3 (en) Compositions and methods for the treatment of viral infections
CY1122192T1 (el) Αντιβακτηριακες σκονες με βαση ανιontiκο διοξειδιο πυριτιου ή τιτανιου εμπλουτισμενες με φαρμακευτικα δραστικα κατιοντα
RU2021139253A (ru) Предотвращение заражения высокопатогенными вирусами путем местного нанесения повидон-йода на слизистые оболочки